T cell receptor gamma joining 1Genealiases: J1 · TCRGJ1
Q-omics provides the consensus-scored TRGJ1 profile across patient tissues and cancer cell-line models. TRGJ1 expression is associated with patient survival in 3 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TRGJ1 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, TRGJ1 RNA expression shows 9,249 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, PRAD, and LSCC as cancer lineages where TRGJ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGJ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGJ1 survival associations across molecular data types. TRGJ1 RNA expression shows survival associations in the most cancer types (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGJ1 RNA expression–survival associations across cancer types. High TRGJ1 expression shows unfavorable associations in COAD, STAD and THYM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for TRGJ1 RNA expression.
This table summarizes TRGJ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRGJ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGJ1 shows higher tumor expression in PRAD. The PRAD box plot shows higher TRGJ1 RNA expression in tumor versus normal tissue (log2 FC = +0.107, t-test p = .025).
This table shows molecular features associated with TRGJ1 in patient tissues and cancer cell lines. In patient samples, TRGJ1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
